The two pharmaceutical companies have reached a major cooperation, the tens of billions of long-acting growth hormone market may face changes

 Growth hormone deficiency, known as dwarfism, is caused by the dysfunction of growth hormone secretion in the pituitary gland
.
In recent years, with the gradual increase in the penetration rate of drug therapy, the domestic market for the treatment of children's growth hormone deficiency has also gradually increased
.
Recently, in this field, the news that the two pharmaceutical companies have reached a huge amount of cooperation has aroused market attention
.
On November 11, Jichuan Pharmaceutical issued an announcement, announcing that it had reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan)
.
Jichuan Pharmaceutical will make a down payment of 224 million yuan to Tianjing Bio, and follow-up payments of no more than 1.
792 billion yuan in milestone payments, with a total payment of 2.
016 billion yuan
.
After the strategic cooperation, Tianjing Bio will continue to lead the phase III clinical trials of Etan growth hormone for the treatment of children's growth hormone deficiency, as well as the production, continuous process optimization and the development of new formulations, and submit it as an applicant for the listing of Etan growth hormone.
License registration application to supply medicine to Jichuan Pharmaceutical
.
Jichuan Pharmaceutical will participate in the cooperation, share the cost, be responsible for expanding other new indications of Etan growth hormone, and be responsible for the commercialization of the product in the Chinese market after the product is approved.
Tianjing Bio will be responsible for clinical, production and academic aspects.
Provide support
.
It is understood that growth hormone deficiency can affect the physical development of children, and it is urgent to strengthen the treatment of this disease
.
From the point of view of treatment, short-acting recombinant human growth hormone is a common treatment option, but its treatment compliance is relatively poor
.
It is expected that the long-acting human growth hormone market is more safe and convenient, and will develop more rapidly in the future
.
"The use of long-acting growth hormone with the same effect as short-acting growth hormone therapy, but with lower injection frequency and higher patient compliance has become an inevitable trend in the development of the industry
.
" Some insiders said
.
According to data forecasts, from 2018 to 2030, the market size of long-acting growth hormone will increase at a compound growth rate of about 43%.
By 2030, this market size may reach 6.
2 billion US dollars, or about 35.
7 billion yuan. .
But it is worth mentioning that, from the current point of view, domestic long-acting growth hormone products are relatively lacking
.
The only long-acting growth hormone preparations that have been marketed are the polyethylene glycol recombinant human growth hormone injections approved by Jinsai Pharmaceutical in 2014
.
From the perspective of R&D competition, currently, only IMAB.
US, Novo Nordisk, Weisheng Pharmaceutical, Anhui Anke and Xiamen Tebao have long-acting growth hormone products under development in China
.
However, compared with China, there are currently 11 long-acting growth hormone drugs in clinical research in the world
.
Two of them have already submitted marketing applications; two projects have been completed in phase III clinical trials; two projects are still in clinical phase III
.
Therefore, in order to better meet the huge domestic market demand, domestic pharmaceutical companies need to continue to work hard
.
Growth hormone is undoubtedly one of the very good tracks, and the industry prospects will be very good
.
This time, the cooperation between Jichuan Pharmaceutical and Tianjing Biotechnology is not only another new attempt to seek new development space, but also the entry of Jichuan Pharmaceutical into the field of human growth hormone reorganization also means that the domestic growth hormone market may be set to Change
.
It is reported that Tianjing Bio's Yitan is currently undergoing phase III clinical trials and is in the first echelon of global long-acting growth hormone research and development.
Compared with the unlisted Weisheng Pharmaceutical, Tianjing Bio is currently listed on the US stock market
.